Virtual Library

Start Your Search

lixuan Chen

Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-08 - Efficacy of Osimertinib in Patients of Advanced Non-Small Cell Lung Cancer with Brain Metastasis: A Retrospective Analysis (Now Available) (ID 1656)

      08:00 - 18:00  |  Author(s): lixuan Chen

      • Abstract
      • Slides


      Osimertinib (AZD9291) is an oral, irreversible, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.The aim of this retrospective study was to evaluate the efficacy of AZD9291 for advanced non-small cell lung cancer(NSCLC) patients with brain metastasis.


      We followed up patients diagnosed with advanced non-small cell lung cancer who were detected with EGFR gene mutation and who received EGFR-TKI from 1st October 2006 to 1st June 2018.Patients finally collected were divided into two groups:One group comprised of 45 patients received first-generation or second-generation EGFR-TKI alone,while other group included 45 patients were given AZD9291.And the 95% confidence interval (CI)and the median progression-free survival (mPFS)were calculated by the Kaplan-Meier method.


      The median progression-free survival(mPFS) was longer with osimertinib than with standard EGFR-TKIs (14.0 months vs. 11.0 months; 95%Cl: 10.160-13.840, P=0.017). The mPFS of patients with brain metastasis was significantly longer with osimertinib than with standard EGFR-TKIs(13.0 months vs. 7.0 months; 95%CI: 6.087-11.913, P=0.020). The mPFS of patients with osimertinib was longer with combined radiotherapy than with not receive radiotherapy(18.0 months vs. 13.0 months; 95%CI:7.066-18.934, P=0.915).


      In patients with non-small cell lung cancer with brain metastases, the median progression-free time of patients with osimertinib was longer than that of patients with first- or second-generation EGFR-TKIs alone, but osimertinib combined with radiotherapy showed no statistical significance compared with no radiotherapy.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.